ストックスクリーナーアプリを入手
7.00
1.51%
0.05
前日終値:
$6.95
開ける：
$6.9
24時間の取引高:
8,553
Relative Volume:
0.01
時価総額：
$27.61M
収益：
-
当期純損益:
$-117.67M
株価収益率:
-2.2654
EPS:
-3.09
ネットキャッシュフロー:
$-101.06M
1週間 パフォーマンス:
-6.80%
1か月 パフォーマンス:
+78.61%
6か月 パフォーマンス:
+2,037%
1年 パフォーマンス:
+1,076%
1日の値動き範囲:
$6.90
$7.11
1週間の範囲:
$6.405
$7.56
52週間の値動き範囲:
$0.2195
$8.36
Athira Pharma Inc Stock (ATHA) Company Profile
名前
Athira Pharma Inc
セクター
電話
(425) 620-8501
住所
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
ATHA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
7.00 | 27.41M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.46 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
799.09 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.99 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.29 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.39 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-19 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-04 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-09-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 開始されました | Rodman & Renshaw | Buy |
| 2022-10-17 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-06-23 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | ダウングレード | Jefferies | Buy → Hold |
| 2022-06-23 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | 開始されました | BTIG Research | Buy |
| 2022-04-21 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Goldman | Neutral |
| 2020-10-13 | 開始されました | Goldman | Buy |
| 2020-10-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-13 | 開始されました | Jefferies | Buy |
| 2020-10-13 | 開始されました | Stifel | Buy |
すべてを表示
Athira Pharma Inc (ATHA) 最新ニュース
Athira Pharma (NASDAQ:ATHA) CEO Mark James Litton Sells 2,586 Shares - Defense World
Worthington, Athira Pharma general counsel, sells $6k in ATHA stock - Investing.com Canada
Athira Pharma CSO Church sells $6k in ATHA stock - Investing.com
Aug Analyst Calls: How 1CM Inc IQ70 stock performs during market turbulence2025 Retail Activity & Short-Term Trading Opportunity Alerts - moha.gov.vn
Athira Pharma CSO Church sells $6k in ATHA stock By Investing.com - Investing.com Nigeria
Immix Biopharma (NASDAQ:IMMX) & Athira Pharma (NASDAQ:ATHA) Critical Survey - Defense World
Athira Pharma Stock Rockets 92% With 5-Day Winning Streak - Trefis
Athira Pharma Licenses Lasofoxifene For Metastatic Breast Cancer, Secures $236 Million Funding - Voice Of HealthCare
Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment - MSN
Why retail investors favor Athira Pharma Inc. stockQuarterly Portfolio Review & Consistent Return Investment Signals - Улправда
How strong is Athira Pharma Inc. stock balance sheetMarket Sentiment Report & Weekly High Return Stock Opportunities - bolumsonucanavari.com
Can Athira Pharma Inc. stock beat analyst upgradesTrade Signal Summary & Precise Buy Zone Identification - Улправда
Does Athira Pharma Inc. stock trade at a discount to peersJuly 2025 Big Picture & Daily Volume Surge Signals - Улправда
Volume Summary: Why retail investors favor Athira Pharma Inc. stockJuly 2025 Technicals & AI Powered Market Entry Ideas - Улправда
Athira Pharma Inc. (ATHA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Mizuho maintains Neutral on Athira Pharma stock after transformative deals By Investing.com - Investing.com Canada
How analysts rate Athira Pharma Inc. stock todayTrade Risk Report & Daily Momentum Trading Reports - Bölüm Sonu Canavarı
Will Athira Pharma Inc. stock benefit from automationWeekly Stock Recap & Reliable Price Action Trade Plans - Улправда
Athira Pharma raises $90 million as Bothell firm shifts focus - The Business Journals
Athira Pharma shares surge after securing rights to phase 3 breast cancer therapy - MSN
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast CancerSlideshow (NASDAQ:ATHA) 2025-12-18 - Seeking Alpha
Finance Watch: Athira Licenses Breast Cancer Drug, Raises Cash To Develop It - Citeline News & Insights
Ligand Pharmaceuticals (NASDAQ: LGND) outlines Athira investment update and disclosure channels - Stock Titan
Athira Pharma, Inc. (ATHA) Stock: Rockets 68% After Phase 3 Lasofoxifene Deal and $90M Private Placement - parameter.io
Athira Pharma Inc.: Growth or Bubble? - StocksToTrade
Why Is Athira Pharma Stock Spiking After Breast Cancer Asset Acquisition? - Sahm
Athira Pharma acquires rights to phase 3 breast cancer drug By Investing.com - Investing.com Nigeria
Athira Pharma stock shot up 60% today – what’s triggering the super rally? - MSN
Nasdaq Gains Over 200 Points; US Inflation Slows To 2.7% - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Athira Pharma, Inc. announced that it expects to receive $89.724073 million in funding - marketscreener.com
Athira Pharma announces license to develop, commercialize lasofoxifene - TipRanks
Athira Pharma (ATHA) Stock Explodes 73% Higher on Breakthrough Cancer Drug Deal - Blockonomi
Athira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally? - Asianet Newsable
Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug - Investing.com Nigeria
Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug By Investing.com - Investing.com South Africa
Is It Too Late to Buy Athira Pharma Inc. Stock? - timothysykes.com
Why Is Athira Pharma Stock (ATHA) Up Today? - TipRanks
Athira Pharma pivots to oncology with new licensing deal - TipRanks
Athira Pharma acquires rights to phase 3 breast cancer drug - Investing.com
Athira Pharma Signs Multiple Material Agreements - TradingView — Track All Markets
Athira Pharma Announces Exclusive License to Lasofoxifene - GlobeNewswire
New breast cancer drug moves into late testing with $236M funding deal - Stock Titan
Can Athira Pharma Inc. stock sustain market leadership2025 Bull vs Bear & Verified Momentum Stock Ideas - Улправда
Athira Pharma Earnings Notes - Trefis
Contrasting Day One Biopharmaceuticals (NASDAQ:DAWN) & Athira Pharma (NASDAQ:ATHA) - Defense World
Entry Recap: Will Athira Pharma Inc stock outperform growth indexesJuly 2025 Update & Free Risk Controlled Daily Trade Plans - moha.gov.vn
Athira Pharma (ATHA) price target increased by 700.00% to 4.08 - MSN
How Athira Pharma Inc. stock trades before earningsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Will Athira Pharma Inc. stock outperform growth indexes2025 Market Overview & Accurate Buy Signal Alerts - Newser
Alzheimer's Disease Market to Evolve Rapidly Over the Next - openPR.com
Athira Pharma Inc (ATHA) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):